Home > Research > Publications & Outputs > Use of biologics in SLE

Research

Links

Text available via DOI:

Keywords

View graph of relations

Use of biologics in SLE: a review of the evidence from a clinical perspective

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

Use of biologics in SLE: a review of the evidence from a clinical perspective. / Aytan , Jayoti ; Bukhari, Marwan A. S.
In: Rheumatology, Vol. 55, No. 5, 01.05.2016, p. 775-779.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Aytan , J & Bukhari, MAS 2016, 'Use of biologics in SLE: a review of the evidence from a clinical perspective', Rheumatology, vol. 55, no. 5, pp. 775-779. https://doi.org/10.1093/rheumatology/kev346

APA

Aytan , J., & Bukhari, M. A. S. (2016). Use of biologics in SLE: a review of the evidence from a clinical perspective. Rheumatology, 55(5), 775-779. https://doi.org/10.1093/rheumatology/kev346

Vancouver

Aytan J, Bukhari MAS. Use of biologics in SLE: a review of the evidence from a clinical perspective. Rheumatology. 2016 May 1;55(5):775-779. Epub 2015 Sept 30. doi: 10.1093/rheumatology/kev346

Author

Aytan , Jayoti ; Bukhari, Marwan A. S. / Use of biologics in SLE : a review of the evidence from a clinical perspective. In: Rheumatology. 2016 ; Vol. 55, No. 5. pp. 775-779.

Bibtex

@article{43dcad31fff84e0395cb1793714d1ec5,
title = "Use of biologics in SLE: a review of the evidence from a clinical perspective",
abstract = "With the explosion in biologics use in rheumatology, newer and smarter ways of using these drugs in different diseases have been advocated. SLE has to date been at the back of the biologics algorithms. Recently, the US Food and Drug Administration and European Medicines Evaluation Agency licensed belimumab for use in SLE, the first drug in >30 years. A clinical review of the evidence that underlies the use of belimumab and other biologics in SLE reveals possible reasons why the results are not as spectacular as they are in other diseases.",
keywords = "lupus, biologics, review",
author = "Jayoti Aytan and Bukhari, {Marwan A. S.}",
year = "2016",
month = may,
day = "1",
doi = "10.1093/rheumatology/kev346",
language = "English",
volume = "55",
pages = "775--779",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "OXFORD UNIV PRESS",
number = "5",

}

RIS

TY - JOUR

T1 - Use of biologics in SLE

T2 - a review of the evidence from a clinical perspective

AU - Aytan , Jayoti

AU - Bukhari, Marwan A. S.

PY - 2016/5/1

Y1 - 2016/5/1

N2 - With the explosion in biologics use in rheumatology, newer and smarter ways of using these drugs in different diseases have been advocated. SLE has to date been at the back of the biologics algorithms. Recently, the US Food and Drug Administration and European Medicines Evaluation Agency licensed belimumab for use in SLE, the first drug in >30 years. A clinical review of the evidence that underlies the use of belimumab and other biologics in SLE reveals possible reasons why the results are not as spectacular as they are in other diseases.

AB - With the explosion in biologics use in rheumatology, newer and smarter ways of using these drugs in different diseases have been advocated. SLE has to date been at the back of the biologics algorithms. Recently, the US Food and Drug Administration and European Medicines Evaluation Agency licensed belimumab for use in SLE, the first drug in >30 years. A clinical review of the evidence that underlies the use of belimumab and other biologics in SLE reveals possible reasons why the results are not as spectacular as they are in other diseases.

KW - lupus

KW - biologics

KW - review

U2 - 10.1093/rheumatology/kev346

DO - 10.1093/rheumatology/kev346

M3 - Journal article

VL - 55

SP - 775

EP - 779

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 5

ER -